FDA Investigator Holly Brevig
Holly Brevig has inspections in 2 countries as of 20 Sep 2023. Holly Brevig has collaborated with a combined 1735 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
5
Last Inspection Date:
20 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
Japan,
United States of America
Co-Investigator(s):
Abdur Rafay Shareef,
Amber G Wardwell,
Angela E Glenn,
Ann M Stewart,
Ann Marie Montemurro,
Ann Marie Schofield,
Anthony C Warchut,
Arie C Menachem,
Barbara T Carmichael,
Bingchen Du,
Bradley Dworak, PhD,
Brenda P King,
Brentley S Collins,
Bruce D Meade,
Burnell M Henry,
Cassandra L Abellard,
CDR Donald Ertel,
CDR Ileana Barreto Pettit,
Christian D Lynch (CDL),
Christine A Harman, PhD,
Cynthia Jim, CSO,
Cynthia L Kelley,
David E Bailey,
David Galler Veety,
Deborah M Trout,
Dusty F Snoeberg,
Ellen P Madigan,
Erik W Koester,
Gene D Arcy,
Hector A Carrero,
Irina Gaberman,
Ivan E Reyes,
Jacqueline Mdiaz Albertini,
Jean Lhu Primmer,
Jennifer L Bridgewater,
Joan Johnson,
Jonathan G Matrisciano,
Jose E Melendez, DDC,
Juanita P Versace,
Julie D Bringger,
Justin A Boyd,
Katherine D Adams,
Katie L Korchinski,
Kenneth H Williams,
Kham Phommachanh,
Laurimer Kuilan Torres,
Linda Thai,
Lisa P Oakes,
Lisa Pierce Oakes,
Lu Deng,
Lucas B Leake,
Malgorzata G Norton,
Margaret Norton,
Marsha W Major,
Maya M Davis,
Megan A Haggerty,
Michael C Kennedy, PhD,
Michele L Forster, PhD,
Mihaly S Ligmond,
Myra K Casey,
Nicholas A Violand,
Olga Simakova,
Omotunde O Osunsanmi,
Pankaj H Amin,
Paraluman S Leonin,
Parul M Patel,
Patsy J Domingo,
Paul L Bellamy,
Paula A Trost,
Phillip E Mclaughlin,
Prabhu P Raju,
Raeann R Wu,
Ramon E Martinez,
Rebecca E Dombrowski,
Robert W Jennings,
Rose M Ashley,
Santos E Camara,
Sarah B Tanksley,
Sharon K Thoma, PharmD,
Sheri L Stephenson,
Stacey S Degarmo,
Steven C Derrick,
Steven M Weinman,
Susan M Jackson,
Susan M Turcovski,
Thuy T Nguyen, LCDR,
Timothy M Martin,
Towanda L Terrell,
Valentino Fiorella,
Vidya B Pai,
Vincent Thomas,
Vioela J Caze,
William D Tingley,
Xiaokuang Lai, PhD,
Yonggang Wang, PhD
Holly Brevig's Documents
Publish Date | Document Type | Title |
---|---|---|
October, 2019 | FDA 483 | Emergent Biodefense Operations Lansing LLC - Form 483, 2019-10-04 |
May, 2023 | FDA 483 | Takeda Pharmaceutical Company Limited - Form 483, 2023-05-24 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more